Edwards Lifesciences (NYSE: EW) insider files Form 144 to sell 583 shares

Rhea-AI Filing Summary

Edwards Lifesciences Corporation insider filed a Form 144 notice for a planned sale of common stock. The filing covers up to 583 shares of common stock to be sold through Charles Schwab & Co., Inc. on or about 12/08/2025 on the NYSE, with an aggregate market value of $50,144.00. The issuer has 580,300,000 shares of common stock outstanding.

The shares to be sold were acquired through equity compensation, specifically restricted stock lapses of 316 shares on 09/14/2024 and 267 shares on 09/14/2025 from Edwards Lifesciences Corporation. The seller represents that they are not aware of any material adverse, nonpublic information about the company’s operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	583	50144.00	580300000	12/08/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/14/2024	Restricted Stock Lapse	EDWARDS LIFESCIENCES CORPORATION			316	09/14/2024	Equity Compensation
Common	09/14/2025	Restricted Stock Lapse	EDWARDS LIFESCIENCES CORPORATION			267	09/14/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Edwards Lifesciences (EW) Form 144 filing disclose?

The Form 144 filing discloses that an insider of Edwards Lifesciences Corporation intends to sell up to 583 shares of the company’s common stock on the NYSE through Charles Schwab & Co., Inc..

How many Edwards Lifesciences (EW) shares are planned to be sold and what is their value?

The notice covers a proposed sale of 583 common shares of Edwards Lifesciences with an aggregate market value of $50,144.00.

When is the Edwards Lifesciences (EW) insider planning to sell the shares?

The approximate date of sale stated in the Form 144 is 12/08/2025.

How were the Edwards Lifesciences (EW) shares being sold acquired?

The shares were acquired as equity compensation through restricted stock lapses, with 316 shares acquired on 09/14/2024 and 267 shares acquired on 09/14/2025 from Edwards Lifesciences Corporation.

How many Edwards Lifesciences (EW) shares are outstanding according to the filing?

The Form 144 states that there are 580,300,000 shares of Edwards Lifesciences common stock outstanding.

What representation does the seller make in the Edwards Lifesciences (EW) Form 144?

The seller represents that they do not know of any material adverse information about the current or prospective operations of Edwards Lifesciences that has not been publicly disclosed.